#JPM24: bluebird is still looking for more financing as it brings sickle cell therapy to market

SAN FRANCISCO — After striking deals for as much as $225 million in financing, bluebird bio’s CEO said the company is still on the lookout for more, including from a future partner or from another source.

“There’s a lot of belief that a gene therapy can’t be profitable,” CEO Andrew…
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks